Co-Diagnostics Announces $3.8M Securities Purchase Agreement

Co-Diagnostics ( (CODX) ) has shared an announcement.

On September 17, 2025, Co-Diagnostics, Inc. announced a securities purchase agreement with institutional investors for a registered direct offering of 9,619,000 shares of common stock at $0.40 per share, expected to close on September 18, 2025. The offering, facilitated by Maxim Group LLC as the sole placement agent, is anticipated to generate gross proceeds of approximately $3.8 million, which the company plans to use for working capital and general corporate purposes. The agreement includes participation rights for investors in future financings and imposes restrictions on the issuance of additional common stock for 30 days post-closing.

The most recent analyst rating on (CODX) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Co-Diagnostics stock, see the CODX Stock Forecast page.

Spark’s Take on CODX Stock

According to Spark, TipRanks’ AI Analyst, CODX is a Neutral.

Co-Diagnostics is currently facing significant financial difficulties, with declining revenues and profitability being the most impactful factors. While there is some bullish momentum in the technical indicators, the overall financial health and valuation concerns weigh heavily on the stock’s attractiveness.

To see Spark’s full report on CODX stock, click here.

More about Co-Diagnostics

Co-Diagnostics, Inc., based in Utah, is a molecular diagnostics company specializing in the development, manufacturing, and marketing of advanced diagnostic technologies. The company focuses on tests designed for the detection and analysis of nucleic acid molecules, utilizing its proprietary technology for applications including the Co-Dx PCR at-home and point-of-care platform and identifying genetic markers beyond infectious diseases.

Average Trading Volume: 6,533,587

Technical Sentiment Signal: Sell

Current Market Cap: $16.07M

Learn more about CODX stock on TipRanks’ Stock Analysis page.